Ana Catalan1,2, Gonzalo Salazar de Pablo2,3, Julio Vaquerizo Serrano2,3, Pierluca Mosillo2,4, Helen Baldwin2, Aranzazu Fernández-Rivas1, Carmen Moreno3, Celso Arango3, Christoph U Correll5,6,7,8, Ilaria Bonoldi2, Paolo Fusar-Poli2,9,10,11. 1. Mental Health Department - Biocruces Bizkaia Health Research Institute, Basurto University Hospital, Faculty of Medicine and Dentistry, University of the Basque Country - UPV/EHU, Biscay, Spain. 2. Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. 3. Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón School of Medicine, IiSGM, CIBERSAM, Complutense University of Madrid, Madrid, Spain. 4. Faculty of Medicine and Surgery, University of Pavia, Pavia, Italy. 5. The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA. 6. Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/ Northwell, Hempstead, NY, USA. 7. Center for Psychiatric Neuroscience, The Feinstein Institutes for Medical Research, Manhasset, NY, USA. 8. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany. 9. OASIS service, South London and Maudsley NHS Foundation Trust, London, UK. 10. Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. 11. National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.
Abstract
BACKGROUND: The clinical high-risk state for psychosis (CHR-P) paradigm has facilitated the implementation of psychosis prevention into clinical practice; however, advancements in adolescent CHR-P populations are less established. METHODS: We performed a PRISMA/MOOSE-compliant systematic review of the Web of Science database, from inception until 7 October 2019, to identify original studies conducted in CHR-P children and adolescents (mean age <18 years). Findings were systematically appraised around core themes: detection, prognosis and intervention. We performed meta-analyses (employing Q statistics and I 2 test) regarding the proportion of CHR-P subgroups, the prevalence of baseline comorbid mental disorders, the risk of psychosis onset and the type of interventions received at baseline. Quality assessment and publication bias were also analysed. RESULTS: Eighty-seven articles were included (n = 4,667 CHR-P individuals). Quality of studies ranged from 3.5 to 8 (median 5.5) on a modified Newcastle-Ottawa scale. Detection: Individuals were aged 15.6 ± 1.2 years (51.5% males), mostly (83%) presenting with attenuated positive psychotic symptoms. CHR-P psychometric accuracy improved when caregivers served as additional informants. Comorbid mood (46.4%) and anxiety (31.4%) disorders were highly prevalent. Functioning and cognition were impaired. Neurobiological studies were inconclusive. PROGNOSIS: Risk for psychosis was 10.4% (95%CI: 5.8%-18.1%) at 6 months, 20% (95%CI: 15%-26%) at 12 months, 23% (95%CI: 18%-29%) at 24 months and 23.3% (95%CI: 17.3%-30.7%) at ≥36 months. INTERVENTIONS: There was not enough evidence to recommend one specific treatment (including cognitive behavioural therapy) over the others (including control conditions) to prevent the transition to psychosis in this population. Randomised controlled trials suggested that family interventions, cognitive remediation and fish oil supplementation may improve cognition, symptoms and functioning. At baseline, 30% of CHR-P adolescents were prescribed antipsychotics and 60% received psychotherapy. CONCLUSIONS: It is possible to detect and formulate a group-level prognosis in adolescents at risk for psychosis. Future interventional research is required.
BACKGROUND: The clinical high-risk state for psychosis (CHR-P) paradigm has facilitated the implementation of psychosis prevention into clinical practice; however, advancements in adolescent CHR-P populations are less established. METHODS: We performed a PRISMA/MOOSE-compliant systematic review of the Web of Science database, from inception until 7 October 2019, to identify original studies conducted in CHR-Pchildren and adolescents (mean age <18 years). Findings were systematically appraised around core themes: detection, prognosis and intervention. We performed meta-analyses (employing Q statistics and I 2 test) regarding the proportion of CHR-P subgroups, the prevalence of baseline comorbid mental disorders, the risk of psychosis onset and the type of interventions received at baseline. Quality assessment and publication bias were also analysed. RESULTS: Eighty-seven articles were included (n = 4,667 CHR-P individuals). Quality of studies ranged from 3.5 to 8 (median 5.5) on a modified Newcastle-Ottawa scale. Detection: Individuals were aged 15.6 ± 1.2 years (51.5% males), mostly (83%) presenting with attenuated positive psychotic symptoms. CHR-P psychometric accuracy improved when caregivers served as additional informants. Comorbid mood (46.4%) and anxiety (31.4%) disorders were highly prevalent. Functioning and cognition were impaired. Neurobiological studies were inconclusive. PROGNOSIS: Risk for psychosis was 10.4% (95%CI: 5.8%-18.1%) at 6 months, 20% (95%CI: 15%-26%) at 12 months, 23% (95%CI: 18%-29%) at 24 months and 23.3% (95%CI: 17.3%-30.7%) at ≥36 months. INTERVENTIONS: There was not enough evidence to recommend one specific treatment (including cognitive behavioural therapy) over the others (including control conditions) to prevent the transition to psychosis in this population. Randomised controlled trials suggested that family interventions, cognitive remediation and fish oil supplementation may improve cognition, symptoms and functioning. At baseline, 30% of CHR-P adolescents were prescribed antipsychotics and 60% received psychotherapy. CONCLUSIONS: It is possible to detect and formulate a group-level prognosis in adolescents at risk for psychosis. Future interventional research is required.
Authors: Elena Dragioti; Joaquim Radua; Marco Solmi; Celso Arango; Dominic Oliver; Samuele Cortese; Peter B Jones; Jae Il Shin; Christoph U Correll; Paolo Fusar-Poli Journal: Mol Psychiatry Date: 2022-04-28 Impact factor: 15.992
Authors: Joseph S DeLuca; Derek M Novacek; Laura H Adery; Shaynna N Herrera; Yulia Landa; Cheryl M Corcoran; Elaine F Walker Journal: Evid Based Pract Child Adolesc Ment Health Date: 2022-03-23
Authors: Michelle A Worthington; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Matcheri Keshavan; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; William S Stone; Ming T Tsuang; Elaine F Walker; Scott W Woods; Tyrone D Cannon Journal: Schizophr Bull Date: 2022-03-01 Impact factor: 7.348
Authors: Paolo Fusar-Poli; Christoph U Correll; Celso Arango; Michael Berk; Vikram Patel; John P A Ioannidis Journal: World Psychiatry Date: 2021-06 Impact factor: 79.683
Authors: Cansu Sarac; Joseph S DeLuca; Zarina R Bilgrami; Shaynna N Herrera; Jonathan J Myers; Matthew F Dobbs; Shalaila S Haas; Therese L Todd; Agrima Srivastava; Rachel Jespersen; Riaz B Shaik; Yulia Landa; Larry Davidson; Anthony J Pavlo; Cheryl M Corcoran Journal: Psychiatr Rehabil J Date: 2021-06-17
Authors: Ana Catalan; Gonzalo Salazar de Pablo; Claudia Aymerich; Stefano Damiani; Veronica Sordi; Joaquim Radua; Dominic Oliver; Philip McGuire; Anthony J Giuliano; William S Stone; Paolo Fusar-Poli Journal: JAMA Psychiatry Date: 2021-06-16 Impact factor: 25.911
Authors: Gonzalo Salazar de Pablo; Filippo Besana; Vincenzo Arienti; Ana Catalan; Julio Vaquerizo-Serrano; Anna Cabras; Joana Pereira; Livia Soardo; Francesco Coronelli; Simi Kaur; Josette da Silva; Dominic Oliver; Natalia Petros; Carmen Moreno; Ana Gonzalez-Pinto; Covadonga M Díaz-Caneja; Jae Il Shin; Pierluigi Politi; Marco Solmi; Renato Borgatti; Martina Maria Mensi; Celso Arango; Christoph U Correll; Philip McGuire; Paolo Fusar-Poli Journal: EClinicalMedicine Date: 2021-06-16